Cargando…
Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats
BACKGROUND: Alzheimer’s disease (AD) is considered to be a neurodegenerative disorder that is characterized by increased oxidative stress. Medicinal plants, with their antioxidant properties, have been used to cure several human diseases. The aim of the current study was to explore the protective an...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5158169/ https://www.ncbi.nlm.nih.gov/pubmed/28003750 http://dx.doi.org/10.2147/NDT.S117469 |
_version_ | 1782481573533188096 |
---|---|
author | Zhou, Li Tan, Sha Shan, Yi-long Wang, Yu-ge Cai, Wei Huang, Xue-hong Liao, Xi-yuan Li, Hai-yan Zhang, Lei Zhang, Bing-jun Lu, Zheng-qi |
author_facet | Zhou, Li Tan, Sha Shan, Yi-long Wang, Yu-ge Cai, Wei Huang, Xue-hong Liao, Xi-yuan Li, Hai-yan Zhang, Lei Zhang, Bing-jun Lu, Zheng-qi |
author_sort | Zhou, Li |
collection | PubMed |
description | BACKGROUND: Alzheimer’s disease (AD) is considered to be a neurodegenerative disorder that is characterized by increased oxidative stress. Medicinal plants, with their antioxidant properties, have been used to cure several human diseases. The aim of the current study was to explore the protective and therapeutic effect of baicalein on AD-induced rats. MATERIALS AND METHODS: Swiss Wistar rats were used in the study. The rats were divided into five groups. Group I: normal control group treated with water; Group II: disease control treated with AlCl(3) to induce the mimicking AD for 4 successive weeks (SW); Group III: normal control group treated with baicalein (5 mg/kg) for 2 SW followed by combination of baicalein and AlCl(3) for 4 SW; Group IV: normal control group treated with baicalein (10 mg/kg) for 2 SW followed by combination of baicalein and AlCl(3) for 4 SW; Group V: normal control group treated with rivastigmine (0.3 mg/kg) for 2 SW followed by combination of rivastigmine and AlCl(3) for 4 SW. Moreover, the therapeutic groups are as follows: Group VI: AD disease control treated with AlCl(3) for 4 SW and serving as the therapeutic positive group; Group VII: AD disease control + baicalein (5 mg/kg) for 12 SW; Group VIII: AD disease control + baicalein (10 mg/kg) for 12 SW; Group IX: AD disease control + rivastigmine (0.3 mg/kg) for 12 SW. Behavioral test, T-maze, and rotarod test were also performed before and after the treatment. At the end of the experimental study, all the rats were sacrificed and their brains were removed and divided into two portions. The first portion was homogenated for estimating the level of acetylcholinesterase (AchE) and acetylcholine (Ach). Another portion was used for histopathological evaluation. RESULTS: The current investigation showed that baicalein significantly reduced the duration of revolving on the rotarod, cage activity, and T-maze activity in a dose-dependent manner compared with the AD control group rats. It also altered the AchE and Ach levels in the brain homogenates. The histopathology study also provides strength to the protective effect of baicalein. CONCLUSION: The current study showed that baicalein significantly (P<0.05) improved the biochemical and histopathological condition of AD in rats. |
format | Online Article Text |
id | pubmed-5158169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-51581692016-12-21 Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats Zhou, Li Tan, Sha Shan, Yi-long Wang, Yu-ge Cai, Wei Huang, Xue-hong Liao, Xi-yuan Li, Hai-yan Zhang, Lei Zhang, Bing-jun Lu, Zheng-qi Neuropsychiatr Dis Treat Original Research BACKGROUND: Alzheimer’s disease (AD) is considered to be a neurodegenerative disorder that is characterized by increased oxidative stress. Medicinal plants, with their antioxidant properties, have been used to cure several human diseases. The aim of the current study was to explore the protective and therapeutic effect of baicalein on AD-induced rats. MATERIALS AND METHODS: Swiss Wistar rats were used in the study. The rats were divided into five groups. Group I: normal control group treated with water; Group II: disease control treated with AlCl(3) to induce the mimicking AD for 4 successive weeks (SW); Group III: normal control group treated with baicalein (5 mg/kg) for 2 SW followed by combination of baicalein and AlCl(3) for 4 SW; Group IV: normal control group treated with baicalein (10 mg/kg) for 2 SW followed by combination of baicalein and AlCl(3) for 4 SW; Group V: normal control group treated with rivastigmine (0.3 mg/kg) for 2 SW followed by combination of rivastigmine and AlCl(3) for 4 SW. Moreover, the therapeutic groups are as follows: Group VI: AD disease control treated with AlCl(3) for 4 SW and serving as the therapeutic positive group; Group VII: AD disease control + baicalein (5 mg/kg) for 12 SW; Group VIII: AD disease control + baicalein (10 mg/kg) for 12 SW; Group IX: AD disease control + rivastigmine (0.3 mg/kg) for 12 SW. Behavioral test, T-maze, and rotarod test were also performed before and after the treatment. At the end of the experimental study, all the rats were sacrificed and their brains were removed and divided into two portions. The first portion was homogenated for estimating the level of acetylcholinesterase (AchE) and acetylcholine (Ach). Another portion was used for histopathological evaluation. RESULTS: The current investigation showed that baicalein significantly reduced the duration of revolving on the rotarod, cage activity, and T-maze activity in a dose-dependent manner compared with the AD control group rats. It also altered the AchE and Ach levels in the brain homogenates. The histopathology study also provides strength to the protective effect of baicalein. CONCLUSION: The current study showed that baicalein significantly (P<0.05) improved the biochemical and histopathological condition of AD in rats. Dove Medical Press 2016-12-09 /pmc/articles/PMC5158169/ /pubmed/28003750 http://dx.doi.org/10.2147/NDT.S117469 Text en © 2016 Zhou et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Zhou, Li Tan, Sha Shan, Yi-long Wang, Yu-ge Cai, Wei Huang, Xue-hong Liao, Xi-yuan Li, Hai-yan Zhang, Lei Zhang, Bing-jun Lu, Zheng-qi Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats |
title | Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats |
title_full | Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats |
title_fullStr | Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats |
title_full_unstemmed | Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats |
title_short | Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats |
title_sort | baicalein improves behavioral dysfunction induced by alzheimer’s disease in rats |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5158169/ https://www.ncbi.nlm.nih.gov/pubmed/28003750 http://dx.doi.org/10.2147/NDT.S117469 |
work_keys_str_mv | AT zhouli baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats AT tansha baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats AT shanyilong baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats AT wangyuge baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats AT caiwei baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats AT huangxuehong baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats AT liaoxiyuan baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats AT lihaiyan baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats AT zhanglei baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats AT zhangbingjun baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats AT luzhengqi baicaleinimprovesbehavioraldysfunctioninducedbyalzheimersdiseaseinrats |